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Insoluble glycogen is an enzymatically modi￿ ed
form of naturally occurring soluble glycogen with
a great adsorbing capacity. It can be metabolized
by phagocytes to glucose. In this study we used
insoluble glycogen intravenously in the experi-
mental endotoxin shock of rats. Wistar male rats
were sensitized to endotoxin by Pb acetate. The
survival of rats were compared in groups of
animals endotoxin shock treated and non-treated
with insoluble glycogen. Furthermore, we have
determined in vitro the binding capacity of in-
soluble glycogen for endotoxin, tumour necrosis
factor alpha, interleukin-1 and secretable phos-
pholipase A2. Use of 10 mg/kg dose of insoluble
glycogen could completely prevent the lethality
of shock induced by LD50 quantity of endotoxin
in rats. All animals treated survived. Insoluble
glycogen is a form of ‘metabolizable internal
adsorbents’. It can potentially be used for treat-
ment of septic shock.
Key words: Glycogen, Tumour necrosis factor,
Interleukin-1, Phospholipase A2, Platelet activating
factor, Endotoxin shock
Introduction
In the pathogenesis of endotoxin or septic
shocks the main roles are played by secondary
mediators, e.g. tumour necrosis factor alpha
(TNF-a), interleukin-1 (IL-1), phospholipase A2
(PLA2) and platelet activating factor (PAF). 1- 5
These substances cause generalized lesions of
capillaries resulting in hypotonia with the symp-
toms of concomitant multiple organ dysfunction
syndrome.1 Numerous biologically potent mater-
ials, toxins, cytokines, enzymes, lipid and pep-
tide mediators can be simultaneously present in
the circulation during septic shock. Blocking
only one of these mediators cannot be en-
ough.6,7 Besides extracorporeal adsorbents,8,9
intravascular adsorbents like kaolin, aluminium
and magnesium silicate were found to have
bene￿cial, simultaneously detoxi￿cating effects
in animal experiments.10 However, at a certain
level, they were also toxic. Therefore, there is a
need to develop drugs regarded as ‘metaboliz-
able internal adsorbents’.
Insoluble glycogen (ISG) is an enzymatically
modi￿ed new form of naturally occurring glyco-
gen. In consequence of its enlarged surface, it
has an increased adsorbent capacity compared
with natural glycogen or amylum. Phagocytes
can engulf ISG and degrade it to glucose in the
lysosomes, helping the metabolism of phagocy-
tosing cells. Insoluble glycogen represents a
potent adsorbing capacity in blood. In phago-
cytes it helps the metabolism during the bio-
logical neutralization of toxic materials. It is a
‘metabolizable internal adsorbent’ able to de-
crease the lethality in endotoxin (Escherichia
coli lipopolysaccharide) induced shock of rats.
Materials and Methods
Preparation of insoluble glycogen
Insoluble glycogen was prepared and made by
our method in our laboratory.11 Brie￿y, the
enzymatic elongation of natural, soluble glyco-
gen took place by phosphorylase-a and glucose
1 phosphate, resulting in a new, arti￿cial form,
called insoluble glycogen (ISG) forming insolu-
ble particles with 1 mm average diameter in
water or buffer milieu. Sterile and endotoxin-
free dishes and devices were used throughout
the preparation. ISG represents an enlarged
surface for aspeci￿c and simultaneous adsorp-
tion of various molecules in a solution. The
suspensions of insoluble glycogen were pre-
pared for intravenous treatment: 20 mg/ml of
ISG was used in sterile and endotoxin-free
phosphated buffer in saline (PBS).
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Wistar male rats (200 g) were presensitized to
endotoxin (E. coli lipopolysaccharide) by intra-
venous (i.v.) injection of 5 mg, endotoxin free
Pb (lead) acetate (Reanal, Hungary). The LD 50
dose of i.v. E. coli lipopolysaccharide (LPS,
endotoxin, ET) was found to be 2 mg, whereas
the LD 100 dose of LPS was 5 mg. Ten mg/kg of
i.v. insoluble glycogen was applied just before
LPS. ISG, Pb acetate, LPS were injected i.v.
through the same needle but from various
syringes in the sequence: ISG, Pb acetate, LPS.
The lethality and survival were evaluated after
12 h. The results were calculated on the basis
of three separate experiments.
The experimental protocol was approved by
the Local Animal Experimental Ethical Commit-
tee in 1996.
Binding assays
99mTc labelling of E. coli LPS (endotoxin), 125I
labelling of human phopholipase A2 (14 kD
puri￿ed in our laboratory), rabbit phosphory-
lase-a (puri￿ed in our laboratory), human re-
combinant TNF-a (prepared by Duda et al.),
human IgG (Human Serobacteriological Insti-
tute, Hungary) were carried out in our labora-
tories. The C3b activating and binding
capabilities of ISG was measured in citrated
rabbit blood by determination of the amount of
C3b consumed during the activation of alter-
native way of complement system. The in vitro
binding capacity of 1 mg of ISG was calculated
for various substances and the masses of bound
materials were expressed in mg of bound
molecules/1 mg of ISG. We have preferred to
use this form of calculation instead of counting
in mols, because this formula re￿ects better the
relations of quantities to each other. For exam-
ple: 0.1mg of phosphorylase-a represents
10- 9M, likewise 0.015 mg of phospholipase A2,
showing that the expression of the masses of
bound molecules in mg and not in M can
describe better the real binding situations on
the surfaces of ISG particles. The results repre-
sent the average values of two separate binding
measurements with duplicated samples (n = 4).
Measurement of chemiluminescence
(CL)
0·5 ml of heparinized rat and human blood
samples were used in diluted forms by phos-
phate buffered saline (PBS) and stimulated by
0·5 mg/ml of zymosan (Mannozym, Human
Serobacteriological Institute, Hungary), ISG and
ISGopsonized with rabbit phosphorylase-a. The
CL, the number of photons emitted by phago-
cytes were measured in 10- 7 M luminol (5-
amino, 2,3-dihydro, 1,4-phtalazinedione, Sigma,
USA) milieu by a Nuclear Chicago Isocap/300
liquid scintillation counter (Searle Industries,
USA) in the off coincidence mode.13
Results
The LD50 dose of E. coli endotoxin (ET ,
lipopolysaccharide, LPS) was found to be 2 mg
in rats sensitized to endotoxin by Pb (lead)
acetate. W e have found that 10 mg/kg dose of
ISG given intravenously, simultaneously with Pb
acetate and ET (by the same needle but from
different syringes in the series: ISG, Pb acetate
and LPS) could completely prevent the lethal
effect of LD 50 dose of ET . In this group, all 12
animals survived (Table 1).
In the pathomechanism of endotoxin shock,
the effects of circulating ET , TNF , IL-1, PLA2,
PAF are regarded to be the main causative
factors. For the explanation of the in vivo
protective effect of ISG in the rat model of
endotoxin shock, we have measured its binding
capacity of these materials in vitro. The aim of
the binding assays was to determine the amount
of these biologically important molecules bound
by ISGaspeci￿cally, by adsorption, in order also
to prove the possibility of the occurrence of the
phenomenon in vivo. Table 2 shows that ISG
could bind ET labelled with 99mTc dose depen-
dently, in vitro.
Insoluble glycogen was found to bind 125I-
labelled human recombinant TNF-a, IL-1, hu-
man secretable PLA2 and human IgG (Table 3).
The greatest binding capacity of ISG was found
on phosphorylase-a, it was still rather high on
IgG, C3b and phospholipase A2, whereas on the
cytokines, TNF-a and IL-1, it was rather low
(Table 3).
Table 4 shows that the luminol ampli￿ed
chemiluminescence of phagocytes. ISG, like
zymosan, increased the chemiluminescence in
the samples of both human and rat bloods.
However, when phosphorylase-a and the ISG
Table 1. Protecting effect of 10 mg/ml insoluble glycogen
(ISG) on the endotoxin (ET) shock of rats. Data calculated
on the basis of three separate experiments
Group of animals Lethality
(number of rats in a group) (number of dead
animals)
1. ISG+ Pb acetate (7) 0
2. Pb acetate+ ET (LD50) (12) 6
3. ISG+ Pb acetate+ ET (LD50) (12) 0
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luminescence elevated signi￿cantly (P, 0·001)
suggesting that the level of intracellular glucose
had been elevated on the in￿uence of phos-
phorylase-a, metabolizing glycogen. These ob-
servations proved functionally (we have also
unpublished morphological evidences) that the
particles of ISG could be internalized by phago-
cytes, and the intracellular glucose produced
could increase the free radical production,6 and
it could serve also as a source of energy for the
phagocytosing cells. These data show that cells
can tolerate insoluble glycogen having dual
effects: transporting toxic materials to the
phagocytes,1 and producing intracellular glu-
cose for the cells.2
Discussion
Insoluble glycogen represents a new molecular
and theoretical approach for the solution of the
therapeutic problems of endotoxin or septic
shock. In these pathologic states, like in other
forms of systemic in￿ammatory response syn-
drome (SIRS), the simultaneous presence of
numerous toxic substances is the main reason
for the dif￿culties.1 Insoluble glycogen partly
follows the principle published previously con-
cerning the bene￿cial effects of adsorbents,
kaolin or silicates, used endogenously in experi-
mental intestinal infections. These materials,
however, are themselves toxic.4 Insoluble glyco-
gen is also a potent adsorbent with the cap-
ability to adsorb, to bind simultaneously many
kinds of molecules in plasma, toxic or non-
toxic, as well. The opsonization of ISG by C3b
and IgG has still an important advantage in
plasma. These molecules enable insoluble glyco-
gen to penetrate into the phagocytes via CR1
and Fc receptors transporting some quantities
of TNF-a, IL-1, PLA2, PAF , LPS, etc. into the
lysosomes of phagocytes simultaneously. The
special advantage of insoluble glycogen is man-
ifested in its capability to improve the meta-
bolism of phagocytes in toxic states. The effects
of triglycerid-rich lipoproteins in preventing
septic death, their in￿uences on the transport
and metabolism of endotoxin or cytokines sug-
gest similar mechanisms as in the case of ISG.15
We have to mention that the protecting effect
of ISG on the lethality of endotoxin shock of
rats could be observed only when we injected
it just before plumbum acetate and LPS. There
was no bene￿cial effect of ISG applied in the
4th hour of shock. This ￿nding suggests that
the ef￿cacy of an adsorbent therapy can be
strongly related to the time of application and
Table 2. Binding of 99mTc E. coli lipopolysaccharide (endotoxin, ET) by 1 mg of
insoluble glycogen (ISG). Data represent the average values of two repeated binding
experiments with duplicated samples (n = 4)
Solution Experimental samples
1 2 3 4
1 mg ISG (0.25 ml) 0.25 0.25 0.25 0.25
99mTc ET (ml) 0 0.20 0.40 0.80
PBS(ml) 1.00 0.80 0.60 0.20
378 C 60 min centrifugation
Pellet (cpm) 33 45100 (23%) 126653 (36%) 285177 (44%)
Supernatant (cpm) 45 149678 (77%) 224151 (64%) 352028 (56%)
Table 3. Binding of molecules by 1 mg of insoluble glyco-
gen (ISG). Data represent the average values of two
repeated binding experiments with duplicated samples
(n = 4)
Types of molecules Mass of bound
molecules (mg)
Phosphorylase-a 0.1
IgG 0.08
C3b 0.04
Human secretable phospholipase A2 0.015
Tumour necrosis factor alpha 0.003
Interleukin 1 0.002
Table 4. Effect of insoluble glycogen (ISG) on the luminol
ampli® ed chemiluminescence of neutrophils in whole hu-
man and rat bloods. The results represent the mean
values SD of three separate experiments wtih duplicated
samples (n= 6)
Samples Chemiluminescence
Number of emitted photons
cpm mean SD (n = 6)
Non-stimulated blood (rat) 816 65
Blood + zymosan (1 mg/ml)
(rat)
2410 133
Blood + ISG (1 mg/ml) (rat) 2250 107
Non-stimulated blood
(human)
2020 820
Blood + zymosan (1 mg/ml)
(human)
7400 1410
Blood + ISG (1 mg/ml)
(human)
7250 980
Blood (human)+
phosphorylase-a adsorbed
to ISG (1 mg/ml)
25400 8520
P , 0.001.
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in the acute forms of toxic shock.16
In the in vitro binding experiments for the
various substances the sedimentation of ISG
particles caused a technical problem during
incubation. This was why we measured the
binding constants using the same amount of
ISG and we tested the gradually elevating
concentrations of the materials. From these
studies it has been apparent that ISG, as a
natural substrate of phosphorylase-a, can bind
this enzyme to the greatest extent. Besides,
there are great differences in the binding
capacities of ISG to the various substances.
From the aspect of therapeutical effects, we
emphasize that ISGcan bind C3b, IgG, endotox-
in, PLA2, TNF-a and IL-1 simultaneously.
According to our unpublished data, ISG ap-
plied i.v. in a concentration of 10 mg/kg did not
result in a signi￿cant change in the level of
blood glucose. Thus, no blood sugar elevating
component can be expected to take part in its
protecting effect in endotoxin shock, where the
fall of blood sugar is regarded as a factor of
lethality.17 The bene￿cial in￿uence of ISG on
the glucose metabolism can be basically related
to the peripheral blood cells, mainly to phago-
cytes. ISG was able to increase the free radical
production in the peripheral granulocytes sug-
gesting that its particles could be readily in-
ternalized and they could be metabolized to
glucose intracellularly, elevating the capability
of cells for increased production of free
radicals.6 Recently we have found that ISGhas a
protective effect in the experimental necrotiz-
ing pancreatitis of dogs.18
Insoluble glycogen is representative of a
family of potentially new drugs with multiple
functions, serving special pharmacological pur-
poses like detoxi￿cation, transportation, etc.,
besides directly helping the metabolism of some
types of cells. For such an aim, the chemical
modi￿cation of various natural, not toxic mater-
ials, mainly of carbohydrates or polynucleotides,
can give further examples in the future, effect-
ing as ‘metabolizable internal adsorbents’.
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